FDA Orange Book · active-ingredient family
Fidaxomicin
Fidaxomicin: 2 brands, 4 generics; first approved May 27, 2011; generic available.
Generic available1 exclusivity period
Generic status & protection
Generic available: 4 ANDA applications approved.
Earliest patent expiry Latest exclusivity ends
Brands (NDA)
2
Generics (ANDA)
4
Listed patents
10
Next patent expiry
Mar 04, 2027
in 4 mo
Brand (NDA) products
Originator applications
Generic (ANDA) products (4)
Abbreviated applications
- FIDAXOMICINSANDOZANDA 2204652026
Approved strengths under this FDA application. Strength Dosage form Route Status TE 200MG TABLET ORAL Rx AB - FIDAXOMICINAPOTEXANDA 2195592026
Approved strengths under this FDA application. Strength Dosage form Route Status TE 200MG TABLET ORAL Rx AB - FIDAXOMICINTORRENTANDA 2203742026
Approved strengths under this FDA application. Strength Dosage form Route Status TE 200MG TABLET ORAL Rx AB - FIDAXOMICINACTAVIS LABS FLANDA 2084432024
Approved strengths under this FDA application. Strength Dosage form Route Status TE 200MG TABLET ORAL Rx AB
Patent & exclusivity timeline
Protection horizon
Patent expiryExclusivity endToday
Marketing exclusivity
Hatch-Waxman
- ODE-367Orphan-drug exclusivity (7 years)
in 3 mo
Listed patents
Orange Book patent file
| Patent | Expires | In | Type |
|---|---|---|---|
| 7906489 | in 4 mo | U-2741 | |
| 8859510 | in 9 mo | U-2741 | |
| 7378508 | in 9 mo | SubstanceProduct | |
| 7863249 | in 9 mo | Product | |
| 7906489*PED | in 10 mo | ||
| 7378508*PED | in 1 yr 3 mo | ||
| 7863249*PED | in 1 yr 3 mo | ||
| 8859510*PED | in 1 yr 3 mo | ||
| 9808530 | in 7 yr 8 mo | Product | |
| 9808530*PED | in 8 yr 2 mo |
Approval history
FDA approval span
First approval
15 yr 8 mo ago
Most recent approval
3 mo ago
Approvals span 2011–2026 across 6 FDA applications.
Brand (NDA) 233%
Generic (ANDA) 467%
Fidaxomicin: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Assyro Intelligence
Ask anything about Fidaxomicin
Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.
Evaluating for a team? Book a demo